Life Expectancy Tables Used in Life Settlements

What a Mortality Table Actually Is

A mortality table (or life table) is a grid of probabilities: for a person of a given age and sex, the likelihood of dying within the next year. String those annual probabilities together and you can compute anything actuarial — the chance of surviving ten more years, the expected number of remaining years of life, the full distribution of possible death ages. Life expectancy is simply a summary statistic read off this curve: the probability-weighted average of remaining lifetime.

Several families of tables exist because different populations die at different rates:

• Population tables, built from national vital statistics (the kind published by government agencies such as the Social Security Administration for its own actuarial work), describe everyone — including the uninsured and uninsurable.
• Insured-lives tables, built from life insurance company experience, describe people who passed underwriting when their policies were issued. Insured lives are systematically healthier than the general population — a phenomenon called selection — so these tables show lower mortality.
• Annuitant tables describe people who bought annuities, a group that self-selects for expecting long lives.

The life settlement market builds on insured-lives tables, most prominently the Valuation Basic Table (VBT) family developed through the Society of Actuaries and used across the industry as a common baseline, with regulatory versions of valuation tables adopted through the NAIC framework for insurer reserving. The insureds in settlement transactions are, by definition, people who once passed life insurance underwriting — which is why starting from insured-lives experience, not general population data, is methodologically essential.

From Table to Individual: The Debit-and-Credit Method

A table describes a population; a life settlement prices one person. The bridge between them is the underwriting method used by independent life expectancy (LE) firms, generally described as a debit-and-credit (or mortality multiplier) approach.

The process runs in three steps. First, the underwriter selects the baseline: the table cell matching the insured’s age, sex, and smoking status — sometimes refined by the risk class the insured originally qualified for. Second, a medical reviewer works through the insured’s records — physician notes, hospitalizations, prescriptions, labs, imaging — assigning debits for conditions that increase mortality (cardiac disease, cancer history, diabetes with complications, cognitive decline, frailty markers) and credits for favorable factors (well-controlled conditions, strong functional status, favorable family history). Third, the accumulated debits and credits become a mortality multiplier applied to the baseline table: a 200% rating means the insured is expected to experience twice the table’s mortality at each age; 150% means one and a half times.

The multiplied mortality curve then yields the outputs buyers use: a mean life expectancy in months, often a median, and the full survival curve showing probabilities year by year. Two subtleties matter for interpretation. The distribution is wide — a 7-year LE does not mean death in year seven; it means a probability-weighted average across outcomes from one year to twenty. And the multiplier interacts with the table’s shape, so the same debits produce different LEs at different ages. The role these reports play in transactions is covered in independent life expectancy reports.

The VBT and Its Updates: When the Baseline Moves

Because so much of the industry keys off the Valuation Basic Table family, updates to it are events. The Society of Actuaries has periodically issued new VBT editions — notably the 2001, 2008, and 2015 generations — each built from more recent insured-lives experience and reflecting the mortality improvement that accumulated between editions. Each new edition generally shows insured lives living longer than the prior one assumed.

When a baseline table lengthens, the effect cascades:

• LE estimates extend. The same insured, same medical file, and same multiplier applied to a longer-lived baseline produces a longer life expectancy.
• Valuations fall. Longer LEs mean more projected premium payments and later death benefits, reducing the present value of every policy priced on the new basis — the arithmetic detailed in life settlement pricing mechanics.
• Portfolios reprice. Existing holdings marked to updated assumptions can show losses even though nothing about the policies changed.

LE underwriters do not adopt new tables mechanically — each firm calibrates its methodology to its own mortality experience, deciding how to blend new tables with proprietary data. But the direction of travel across the market’s history has been consistent: successive table generations and methodology refinements have generally lengthened estimates, embedding the lesson that betting on short lifespans is the riskier side of the error. That lesson was learned most brutally in the late-2000s revisions, when methodology changes at the major firms repriced the whole market — the defining episode explored in longevity risk and the life settlement market.

Table / Concept	What It Describes	Role in Life Settlements	Key Caution
Population life tables	Mortality of the general public from vital statistics	Background reference only	Overstates mortality of insured lives
Insured-lives tables (VBT family)	Mortality of people who passed insurance underwriting	Standard baseline for LE underwriting	Each new edition has generally lengthened lifespans
Annuitant tables	Mortality of annuity purchasers	Longevity-market reference	Self-selected long-lived group
Mortality multiplier (debits/credits)	Individual health adjustment to the baseline	Converts medical records into a personalized curve	Judgment-based; varies by firm
Mortality improvement scale	Projected future decline in death rates	Extends estimates for medical progress	Most uncertain assumption; compounds over time
Actual-to-expected (A/E) study	Firm’s predicted vs. observed deaths	Calibration evidence for an LE firm’s accuracy	Past calibration does not guarantee future accuracy

Mortality Improvement: The Table’s Forward-Looking Dimension

A raw table is a snapshot of past experience, but a life settlement is a bet on the future — an insured with a ten-year expectancy will be alive through a decade of medical progress. Underwriters therefore layer mortality improvement assumptions onto base tables: projections of how death rates at each age will decline over the coming years.

Improvement assumptions are the most genuinely uncertain part of the apparatus, because they amount to forecasting medicine and public health:

• Historical improvement has been persistent but uneven. Cardiovascular mortality fell dramatically over recent decades; progress against other causes has been slower; and some U.S. populations have experienced periods of stagnation or reversal.
• Improvement compounds. Small annual improvement rates, applied over a fifteen-year horizon, meaningfully extend expected lifespans — so the assumption chosen moves valuations even when the base table is agreed.
• Improvement is condition-dependent. A breakthrough therapy for a common impairment extends lives across every portfolio holding that impairment simultaneously — the correlated extension risk that diversification cannot remove.

Actuarial bodies publish improvement scales for pension and insurance work, and LE firms adapt these ideas to the impaired senior population they underwrite — a population where improvement may behave differently than in the general insured pool. For investors, improvement assumptions are a standing item in due diligence; for sellers, they are invisible but consequential, quietly shaping every estimate. The buyer-side management of this uncertainty is described in how life settlement investors make money.

Why Different Firms Produce Different Estimates

Sellers are often startled that two reputable LE firms, reading the same medical records, return estimates months or even years apart. The divergence is structural, not sloppy — it flows from legitimate methodological choices at every layer:

• Base table and calibration. Firms anchor to different table editions, blended and adjusted against each firm’s proprietary mortality experience from its own past assessments.
• Debit-credit philosophy. How many debits a given cardiac history warrants, how to weigh a recent-but-treated cancer, how much credit strong functional status earns — these are judgment frameworks that differ by firm.
• Improvement assumptions. Different projected improvement produces different tails, especially for longer-LE insureds.
• Data interpretation. Incomplete records force conservative defaults, and firms differ in what they assume about gaps.

The market’s response to divergence is procedural: buyers typically commission two independent reports (a practice reinforced after the 2000s), then blend them, average them, or lean toward the longer figure. Firms also publish actual-to-expected (A/E) studies — comparing deaths their past estimates predicted against deaths that occurred — as calibration evidence; a firm whose A/E runs near 100% is demonstrating its numbers mean what they say. The consumer-protection dimension of independence — why the estimate must come from firms with no stake in the transaction’s price — is a lesson written in the market’s fraud history, catalogued in life settlement scams to avoid.

From Table to Offer: How the Numbers Reach Your Price

Trace a single transaction to see the tables at work. A 78-year-old policyholder with a documented cardiac history submits medical records through a broker. Two LE firms review the file: each anchors to its calibrated baseline for a 78-year-old male nonsmoker, assigns debits for the cardiac condition and credits for otherwise strong health, and produces its estimate along with a survival curve. Suppose the estimates cluster around a given horizon but differ by several months — the buyer reconciles them conservatively.

The buyer’s model then walks the survival curve year by year: in each future year, it weights the premiums that must be paid if the insured is alive against the probability-weighted death benefit received, discounts everything to present value at the required return, and derives the maximum supportable price. The offer that reaches the seller sits below that ceiling by the buyer’s margin and transaction costs — which is why competition among multiple bidders matters so much in closing that gap.

Every table-related force described in this article is embedded in that number: the insured-lives baseline, the firm’s calibration, the debit-credit judgment on the medical file, the improvement assumption in the curve’s tail, and the buyer’s conservatism about all of it. Documented within the framework the U.S. Government Accountability Office described in GAO-10-775, offers typically land at 10–35% of face value — often four to eight times cash surrender value — with the LE estimate the single largest determinant of where in that range a given policy falls. The complete valuation chain appears in discount rates and life settlement pricing.

What Policyholders Should Know About the Tables Behind Their Offer

The actuarial machinery is the buyer’s problem to run — but a seller who understands a few of its properties can navigate the process more effectively.

You cannot shop the table, but you can complete the file. The baseline tables and methodologies are fixed by the underwriting firms; what a seller controls is the medical evidence. Complete, current records let the debit-credit process see the insured’s actual condition. Gaps are resolved conservatively — toward longer LE and a lower offer — so assembling documentation before the process starts is the highest-yield preparation available.

A longer-than-expected LE is not an insult; a shorter one is not a promise. The estimate is a probability-weighted average over a wide distribution, produced for pricing purposes. It is neither a medical prognosis nor a prediction about any individual’s actual lifespan.

Divergent reports are normal — ask how they were used. A seller may reasonably ask a broker which firms underwrote the file and how differing estimates were reconciled in the offers presented.

Table risk cuts both ways in your decision. If the market’s tables run long and you are in fact seriously impaired, offers may understate your policy’s economic value to a buyer — an argument for competition among bidders. If you are healthier than your file suggests, the reverse holds.

The estimate is one input in a bigger decision. Selling still means permanently giving up the death benefit, potential tax consequences under the IRS three-tier framework, and possible effects on means-tested benefits — considerations that begin with what a life settlement is and belong in front of an independent adviser before any signature.

---

Frequently Asked Questions

What life expectancy tables are used in life settlements?

The industry’s standard baselines come from insured-lives mortality tables, most prominently the Valuation Basic Table (VBT) family developed through the Society of Actuaries, with editions such as the 2001, 2008, and 2015 tables reflecting successively more recent experience. Independent life expectancy underwriting firms anchor to these tables — calibrated against their own proprietary mortality data — and then adjust for each insured’s health using a debit-and-credit method. Population tables from vital statistics are not used directly, because insured lives are systematically healthier.

How do underwriters turn a mortality table into my personal life expectancy estimate?

Through the debit-and-credit (mortality multiplier) method. The underwriter starts from the table cell matching your age, sex, and smoking status, then a medical reviewer works through your records assigning debits for conditions that raise mortality and credits for favorable factors. The net result becomes a multiplier — say 175% of table mortality — applied across the baseline curve. From that adjusted curve, the firm computes your mean life expectancy in months plus a full year-by-year survival distribution that buyers use in pricing.

Why did life expectancy estimates get longer over the years?

Two compounding reasons. First, each new generation of insured-lives tables — built from more recent experience — has generally shown people living longer than the prior edition assumed, reflecting real mortality improvement. Second, the major underwriting firms revised their methodologies in the late 2000s after data showed their estimates ran short, lengthening estimates market-wide and impairing portfolios priced on the older numbers. The industry has leaned conservative ever since, because underestimating lifespans proved to be the costlier error.

What is a mortality multiplier or debit rating in a life expectancy report?

It is the summary of how the insured’s health compares to the baseline table population. A multiplier of 100% means table-standard mortality; 200% means the reviewer’s debits for documented conditions imply twice the table’s death rates at each age, producing a shorter life expectancy; below 100% implies better-than-table health. The multiplier interacts with the table’s shape, so identical ratings yield different life expectancies at different ages. It is a pricing construct, not a medical diagnosis.

Why do two life expectancy companies give different estimates from the same medical records?

Because legitimate methodological choices differ at every layer: which table edition anchors the baseline, how each firm calibrates it against proprietary experience from its own past assessments, how aggressively debits and credits are assigned for particular conditions, what mortality improvement is projected, and how gaps in records are treated. Divergence of months — sometimes more — is normal. Buyers manage it by commissioning two independent reports and reconciling conservatively, often blending them or leaning toward the longer estimate.

Does a longer life expectancy estimate mean a lower offer for my policy?

Generally yes, and the mechanics are direct: a longer estimate means the buyer projects more years of premium payments before receiving the death benefit, and a later benefit is worth less in present-value terms. That is why the LE estimate is the single most influential input in the offer — typically more consequential than interest rates or competition. It is also why complete medical documentation matters: undocumented conditions cannot generate debits, and unresolved gaps default toward longer estimates and lower prices.

What is mortality improvement and why is it built into the tables?

Mortality improvement is the long-run tendency of death rates to decline over time as medicine and living conditions advance. Because a purchased policy may not mature for a decade or more, underwriters project improvement into the future — meaning today’s estimate assumes the insured benefits from years of medical progress that has not happened yet. It is the most uncertain assumption in the process: improvement compounds over long horizons, varies by condition and population, and a breakthrough therapy can extend many insureds’ lives simultaneously.

Can I see or challenge the life expectancy report used to price my policy?

Practices vary, but you can and should ask. A seller working with a licensed broker can request to know which underwriting firms evaluated the file, what the estimates were, and how divergent reports were reconciled in the offers presented. If the file was incomplete — missing recent specialist records, for example — supplying the missing documentation and requesting re-underwriting is a legitimate step that sometimes changes the estimate. Your state’s disclosure rules and the broker’s duty to you support these questions.

Related Reading

• Independent Life Expectancy Reports
• Life Expectancy Assessment Life Settlement
• Longevity Risk Life Settlement Market
• Life Settlement Pricing Mechanics

---

Pine Lake Life Solutions does not purchase life insurance policies and does not provide legal, tax, or investment advice. Information provided is for educational purposes only. Eligibility for any option, including life settlements, is not guaranteed and depends on individual circumstances, policy terms, underwriting, and market conditions. Consult independent legal, tax, or financial professionals before making decisions regarding a life insurance policy.